ANDA 90248, held by Strides Pharma Intl. Alprazolam.
As of Nov 15, 2026, ANDA 90248 (Alprazolam), held by Strides Pharma Intl, was first approved by FDA on Sep 17, 2010, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 17, 2010 | Original application | Approved | None posted |
| Alprazolam0.25MG · tablet;oral | Alprazolam | Discontinued |
| Alprazolam0.5MG · tablet;oral | Alprazolam | Discontinued |
| Alprazolam1MG · tablet;oral | Alprazolam | Discontinued |
| Alprazolam2MG · tablet;oral | Alprazolam | Discontinued |
| Apr 11, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 11, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 11, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 31, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 17, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters